Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market Trends

Report ID: GMI11664
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Amyotrophic Lateral Sclerosis Treatment Market Trends

The expansion of the market is significantly driven by the development of novel drug therapies. Recent advancements in understanding the genetic and molecular mechanisms underlying ALS have led to the identification of new therapeutic targets. This has fuelled the development of innovative treatments, including gene therapies, antisense oligonucleotides, and neuroprotective agents. Antisense oligonucleotides, which can modulate the expression of specific genes, have shown promise in clinical trials, resulting in accelerated approvals by regulatory agencies. Additionally, neuroprotective agents, which aim to protect nerve cells from damage and slow disease progression, are being explored, further expanding the range of therapeutic options.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for amyotrophic lateral sclerosis treatments was valued at USD 713.3 million in 2023 and is projected to grow at a 5.5% CAGR from 2024 to 2032, driven by the rising incidence of ALS, increased awareness, advancements in therapeutic technologies, and the development of novel treatment options.

The market is segmented into medication, stem cell therapy, and other treatment types. In 2023, the medication segment dominated the market, accounting for USD 479.7 million.

The North American market for ALS treatments is expected to grow at a 5.2% CAGR, reaching USD 515.6 million by 2032. The U.S. represents a significant portion of this market, driven by the high prevalence of the disease and a robust healthcare infrastructure.

Prominent companies in the ALS treatment industry include AB Science, Biogen Inc., Biohaven Pharmaceutical (a subsidiary of Pfizer, Inc.), BrainStorm Therapeutics, Inc., Corestemchemon Inc., Eledon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals, Inc., and ITF Pharma GmbH. These companies have either commercial drugs available or are in clinical development phases.